JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Primary Antibodies / IHC Antibodies

Phospho-EIF4G1 (Ser1232) Antibody

SKU : BHA10560414

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

CUSABIO TECHONOLOGY LLC

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	CSB-PA987086
Categories	Primary Antibodies ; Phospho Antibodies
Clonality	polyclonal
Description	eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis De Gregorio, E. et al. (1998) RNA 4, 828-836. Ohlmann, T. et al. (1996) EMBO J. 15, 1371-1382. Borman, A.M. and Kean, K.M. (1997) Virology 237, 129-136. Gradi, A. et al. (1998) Mol Cell Biol 18, 334-42.
Host	Rabbit
Immunogen	Peptide sequence around phosphorylation site of serine 1232 (P-V-S(p)-P-L) derived from Human eIF4G.
Involvement In Disease	Parkinson disease 18 (PARK18)
Raised In	Rabbit
Reactivity	Human
Regulatory	RUO
Relevance	eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis De Gregorio, E. et al. (1998) RNA 4, 828-836. Ohlmann, T. et al. (1996) EMBO J. 15, 1371-1382. Borman, A.M. and Kean, K.M. (1997) Virology 237, 129-136. Gradi, A. et al. (1998) Mol Cell Biol 18, 334-42.
Species	Homo Sapiens (Human)
Specificity	The antibody detects endogenous level of eIF4G only when phosphorylated at serine 1232.

Uniprot	Q04637
Database Links	HGNC:3296 OMIM:600495 KEGG:hsa:1981 STRING:9606.ENSP00000338020 UniGene:Hs.433750
Function	Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome.
Protein Families	Eukaryotic initiation factor 4G family

Buffer	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Format	liquid
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
Purity	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Storage	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Applications

ELISA, WB, IHC

Description

ELISA ; WB ; IHC, WB ; ELISA ; IHC

Dilution

WB	1:500-1:1000
IHC	1:50-1:100

Tested Application

ELISA,WB,IHC;WB:1:500-1:1000,IHC:1:50-1:100

Datasheet
ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHA10560414	CSB-PA987086	100ul	$360		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.